These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 18574662)

  • 21. Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis.
    Takata T; Aizawa K; Shimizu A; Sakakibara S; Watabe H; Totsuka K
    J Infect Chemother; 2004 Apr; 10(2):76-85. PubMed ID: 15160299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monte Carlo simulation for evaluation of the efficacy of carbapenems and new quinolones against ESBL-producing Escherichia coli.
    Nakamura T; Shimizu C; Kasahara M; Okuda K; Nakata C; Fujimoto H; Okura H; Komatsu M; Shimakawa K; Sueyoshi N; Ura T; Satoh K; Toyokawa M; Wada Y; Orita T; Kofuku T; Yamasaki K; Sakamoto M; Nishio H; Kinoshita S; Takahashi H
    J Infect Chemother; 2009 Feb; 15(1):13-7. PubMed ID: 19280294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
    Crandon JL; Bulik CC; Nicolau DP
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4352-6. PubMed ID: 19770286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region.
    Roberts JA; Kwa A; Montakantikul P; Gomersall C; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2011 Mar; 37(3):225-9. PubMed ID: 21168997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An epidemiological study of the susceptibility and frequency of multiple-drug-resistant strains of Pseudomonas aeruginosa isolated at medical institutes nationwide in Japan.
    Tsuji A; Kobayashi I; Oguri T; Inoue M; Yabuuchi E; Goto S
    J Infect Chemother; 2005 Apr; 11(2):64-70. PubMed ID: 15856373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MIC score, a new tool to compare bacterial susceptibility to antibiotics application to the comparison of susceptibility to different penems of clinical strains of Pseudomonas aeruginosa.
    Bretonnière C; Maitte A; Caillon J; Potel G; Boutoille D; Jacqueline C; Guitton C
    J Antibiot (Tokyo); 2016 Nov; 69(11):806-810. PubMed ID: 27025352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comparison of antimicrobial use density (AUD) of carbapenem antibacterial agents and investigation of the drug susceptibility of Pseudomonas aeruginosa in 3 hospitals in southern Ibaraki Prefecture, Japan].
    Oishi T; Hitomi S; Kamoshita M; Fukue H; Kawahata D; Fukutake K
    Rinsho Byori; 2008 Jul; 56(7):570-6. PubMed ID: 18709988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
    Lewis SJ; Kays MB; Mueller BA
    J Clin Pharmacol; 2016 Oct; 56(10):1277-87. PubMed ID: 26919659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
    Valenza G; Seifert H; Decker-Burgard S; Laeuffer J; Morrissey I; Mutters R;
    Int J Antimicrob Agents; 2012 Mar; 39(3):255-8. PubMed ID: 22230334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phenotypic characterization and colistin susceptibilities of carbapenem-resistant of Pseudomonas aeruginosa and Acinetobacter spp.
    Mohanty S; Maurya V; Gaind R; Deb M
    J Infect Dev Ctries; 2013 Nov; 7(11):880-7. PubMed ID: 24240048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrating pharmacokinetics, pharmacodynamics and MIC distributions to assess changing antimicrobial activity against clinical isolates of Pseudomonas aeruginosa causing infections in Canadian hospitals (CANWARD).
    Zelenitsky SA; Rubinstein E; Ariano RE; Zhanel GG;
    J Antimicrob Chemother; 2013 May; 68 Suppl 1():i67-72. PubMed ID: 23587780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation.
    Dong J; Xiong W; Chen Y; Zhao Y; Lu Y; Zhao D; Li W; Liu Y; Chen X
    Int J Antimicrob Agents; 2016 Mar; 47(3):202-9. PubMed ID: 26895604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.
    Samtani MN; Flamm R; Kaniga K; Nandy P
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2360-4. PubMed ID: 20385857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of doripenem.
    Sahm D
    Clin Infect Dis; 2009 Aug; 49 Suppl 1():S11-6. PubMed ID: 19619017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations.
    Ohata Y; Tomita Y; Nakayama M; Kozuki T; Sunakawa K; Tanigawara Y
    Drug Metab Pharmacokinet; 2011; 26(5):523-31. PubMed ID: 21747200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Classification of OprD sequence and correlation with antimicrobial activity of carbapenem agents in Pseudomonas aeruginosa clinical isolates collected in Japan.
    Sanbongi Y; Shimizu A; Suzuki T; Nagaso H; Ida T; Maebashi K; Gotoh N
    Microbiol Immunol; 2009 Jul; 53(7):361-7. PubMed ID: 19563394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between the usage of carbapenem antibiotics and the incidence of imipenem-resistant Pseudomonas aeruginosa.
    Fujimura S; Nakano Y; Sato T; Shirahata K; Watanabe A
    J Infect Chemother; 2007 Jun; 13(3):147-50. PubMed ID: 17593500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic/pharmacodynamic modeling and simulation to determine effective dosage regimens for doripenem.
    Katsube T; Yano Y; Wajima T; Yamano Y; Takano M
    J Pharm Sci; 2010 May; 99(5):2483-91. PubMed ID: 19904828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and monte carlo simulations of doripenem in patients with febrile neutropenia.
    Stein GE; Kulhanek G; Smith CL; Kuti JL; Nicolau DP; Scharmen A; Farnum C; Tran M; Kalra A; Havlichek DH
    Ann Pharmacother; 2012 Oct; 46(10):1281-6. PubMed ID: 23012385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Investigation on optimal regimen of ceftazidime against infection caused by Pseudomonas aeruginosa using Monte Carlo simulation].
    Mikamo H
    Jpn J Antibiot; 2007 Dec; 60(6):387-93. PubMed ID: 18447208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.